Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

Inclusion Criteria: * Subjects at least 18 years of age * Subjects who have the ability to understand and sign an informed consent form and provide Health Insurance Portability and Accountability Act (HIPAA) authorization. * Subjects who are candidate for routine, uncomplicated cataract surgery. * Subjects who are not of childbearing potential or subjects who have a negative urine pregnancy test result at screening. * Subjects must be willing and able to comply with all treatment and follow- up procedures. Exclusion Criteria: * Subjects who have known hypersensitivity or contraindication to the study drug or its components. * Subjects who have a history or presence of chronic generalized systemic disease that the investigator feels might increase the risk to the subject or compound the result of the study. * Subjects who have a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up. * Subjects with elevated intraocular pressure (\>/= 21 mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye. * Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the non-study eye. * Subjects who have had ocular surgery in the study eye within 3 months or in the fellow eye within 2 weeks prior to the screening visit. * Women who are pregnant or breast feeding. * Subjects who have participated in an investigational drug or device study within the last 30 days. * Subjects previously randomized in this study.